ReviewTranslational andrology and urology2021
Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review.
Review in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Systematic Literature Review on Economic Evaluations and Health Economic Models in Metastatic Castration-Sensitive Prostate Cancer.Current oncology (Toronto, Ont.) · 2025Pooled it
- The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development.Frontiers in cell and developmental biology · 2026Review
- Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer.Prostate international · 2025Article
- Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer.The Prostate · 2025Article
- Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review.Current oncology (Toronto, Ont.) · 2025Review
- A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines.Targeted oncology · 2025Article
- Article
- Factors Guiding Clinical Decision-Making in Genitourinary Oncology.Cancer medicine · 2024Review
- Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing.World journal of oncology · 2024Article
- The Current Therapeutic Landscape for Metastatic Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer.Cancer cell international · 2024Article
- Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.Frontiers in oncology · 2024Article
- Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.World journal of urology · 2023Review
- Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer.BMC cancer · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer continues to be one of the most commonly diagnosed cancers in men globally and a leading cause of male cancer deaths. The landscape of metastatic hormone-sensitive prostate cancer has significantly changed over the past decade. For many years, androgen deprivation therapy alone through surgical or chemical castration was the mainstay of treatment yielding limited 5-year survival rates. New treatment approaches using Docetaxel chemotherapy or androgen receptor pathway inhibitors to intensify upfront systemic therapy have resulted in significantly improved survival rates compared to androgen deprivation therapy alone. Clinicians are now equipped with an arsenal of drugs capable of prolonging life for metastatic hormone-sensitive prostate cancer patients. Furthermore, new treatment modalities are being tested in clinical trials making treatment of metastatic hormone-sensitive prostate cancer an extremely dynamic space. In this narrative review, we provide an overview of the key systemic treatments for metastatic hormone-sensitive prostate cancer, namely androgen deprivation therapy, novel androgen receptor pathway inhibitors and Docetaxel. We summarise a series of landmark trials that have led to the integration of novel androgen receptor pathway inhibitors and docetaxel into the treatment paradigm for metastatic hormone-sensitive prostate cancer. Lastly, we discuss nursing, financial and side-effect considerations pertaining to the use of these drugs. This article aims to give its readers an understanding of the evidence and clinical aspects of novel therapies in metastatic hormone-sensitive prostate cancer as they become increasingly available for use around the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.